Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
